Trial Information
Assessment of Liver Cancer Response to Transcatheter Arterial Chemoembolization Using Functional Triple-Phase MultiHance-Enhanced MRI
Inclusion Criteria:
- Outpatients between the ages of 18 - 80 seen in the cardiovascular and interventional
radiology clinic who are scheduled for TACE.
- INR<1.4
- Platelet count > 80,000
Exclusion Criteria:
- Contraindications to TACE procedure
- Unable to have an MRI Scan
- Allergy or hypersensitivity reactions to gadolinium or any other ingredients,
including benzyl alcohol
- Patients with sickle cell anemia , hemoglobinopathies and other hemolytic anemias
- Known clinical hypersensitivity or a history of asthma or allergic respiratory
disorders
- Patients with advanced renal failure (those currently requiring dialysis or with a
Glomerular Filtration Rate<15cc/min)
- Pregnancy
Type of Study:
Interventional
Study Design:
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Outcome Measure:
The primary outcome measurement is agreement of tumor necrosis using triple-phase MultiHance-enhanced MRI, with the percent necrosis seen in patients following surgery or tissue biopsy.
Outcome Time Frame:
2007-2010
Safety Issue:
No
Principal Investigator
Ihab Kamel
Investigator Role:
Principal Investigator
Investigator Affiliation:
The Johns Hopkins University
Authority:
United States: Institutional Review Board
Study ID:
J06108
NCT ID:
NCT00539253
Start Date:
September 2007
Completion Date:
December 2012
Related Keywords:
- Hepatocellular Carcinoma
- liver cancer
- transarterial chemoembolization
- Carcinoma
- Liver Neoplasms
- Carcinoma, Hepatocellular
Name | Location |
The Johns Hopkins Hospital |
Baltimore, Maryland 21205 |